Rachel M Lestz1, Barbara A Fivush, Meredith A Atkinson. 1. Division of Nephrology, Children's Hospital of Los Angeles, 4650 Sunset Boulevard, Nephrology Mail Stop #40, Los Angeles, CA, 90027, USA, rlestz@chla.usc.edu.
Abstract
BACKGROUND: Higher doses of erythropoiesis-stimulating agents (ESA) have been associated with an increased risk of adverse outcomes in adults with chronic kidney disease (CKD) and end-stage kidney disease (ESRD), but to our knowledge no trials have been performed in children. We examined the association between ESA dose and all-cause mortality in a prevalent pediatric dialysis population. METHODS: Retrospective cohort study utilizing national data on all prevalent dialysis patients aged <18 years from the Centers for Medicare and Medicaid Services' 2005 ESRD Clinical Performance Measures (CPM) project, linked to 18-month mortality records from the United States Renal Data System. Multivariate Cox proportional hazards regression was performed to determine the risk of mortality by mean weekly ESA dose. RESULTS: Eight-hundred and twenty-nine children were included in the analysis; 7 % died during follow-up. A higher proportion of patients receiving ESA doses in the highest category (erythropoietin ≥350 units/kg/week or darbepoetin ≥1.5 units/kg/week) died (50 % vs 28 %, p = 0.002), and also demonstrated a trend toward lower hemoglobin (11.0 vs 11.4 g/dL, p = 0.05). In multivariate analysis, patients receiving the highest dose of ESA demonstrated an increased risk of mortality (hazard ratio 3.37; p value <0.01). CONCLUSION: Higher ESA dose is independently associated with mortality in children on chronic dialysis.
BACKGROUND: Higher doses of erythropoiesis-stimulating agents (ESA) have been associated with an increased risk of adverse outcomes in adults with chronic kidney disease (CKD) and end-stage kidney disease (ESRD), but to our knowledge no trials have been performed in children. We examined the association between ESA dose and all-cause mortality in a prevalent pediatric dialysis population. METHODS: Retrospective cohort study utilizing national data on all prevalent dialysis patients aged <18 years from the Centers for Medicare and Medicaid Services' 2005 ESRD Clinical Performance Measures (CPM) project, linked to 18-month mortality records from the United States Renal Data System. Multivariate Cox proportional hazards regression was performed to determine the risk of mortality by mean weekly ESA dose. RESULTS: Eight-hundred and twenty-nine children were included in the analysis; 7 % died during follow-up. A higher proportion of patients receiving ESA doses in the highest category (erythropoietin ≥350 units/kg/week or darbepoetin ≥1.5 units/kg/week) died (50 % vs 28 %, p = 0.002), and also demonstrated a trend toward lower hemoglobin (11.0 vs 11.4 g/dL, p = 0.05). In multivariate analysis, patients receiving the highest dose of ESA demonstrated an increased risk of mortality (hazard ratio 3.37; p value <0.01). CONCLUSION: Higher ESA dose is independently associated with mortality in children on chronic dialysis.
Authors: David A Goodkin; Douglas S Fuller; Bruce M Robinson; Christian Combe; Richard Fluck; David Mendelssohn; Tadao Akizawa; Ronald L Pisoni; Friedrich K Port Journal: J Am Soc Nephrol Date: 2010-12-16 Impact factor: 10.121
Authors: R N Foley; P S Parfrey; J Morgan; P E Barré; P Campbell; P Cartier; D Coyle; A Fine; P Handa; I Kingma; C Y Lau; A Levin; D Mendelssohn; N Muirhead; B Murphy; R K Plante; G Posen; G A Wells Journal: Kidney Int Date: 2000-09 Impact factor: 10.612
Authors: Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto Journal: N Engl J Med Date: 2009-10-30 Impact factor: 91.245
Authors: Dagmara Borzych-Duzalka; Yelda Bilginer; Il Soo Ha; Mustafa Bak; Lesley Rees; Francisco Cano; Reyner Loza Munarriz; Annabelle Chua; Silvia Pesle; Sevinc Emre; Agnieszka Urzykowska; Lily Quiroz; Javier Darío Ruscasso; Colin White; Lars Pape; Virginia Ramela; Nikoleta Printza; Andrea Vogel; Dafina Kuzmanovska; Eva Simkova; Dirk E Müller-Wiefel; Anja Sander; Bradley A Warady; Franz Schaefer Journal: J Am Soc Nephrol Date: 2013-03-07 Impact factor: 10.121
Authors: Ioannis Koulouridis; Mansour Alfayez; Thomas A Trikalinos; Ethan M Balk; Bertrand L Jaber Journal: Am J Kidney Dis Date: 2012-08-22 Impact factor: 8.860
Authors: Alan S Kliger; Robert N Foley; David S Goldfarb; Stuart L Goldstein; Kirsten Johansen; Ajay Singh; Lynda Szczech Journal: Am J Kidney Dis Date: 2013-07-25 Impact factor: 8.860
Authors: Meredith A Atkinson; Ji Young Kim; Cindy N Roy; Bradley A Warady; Colin T White; Susan L Furth Journal: Pediatr Nephrol Date: 2014-11-08 Impact factor: 3.714
Authors: Mark R Hanudel; Michele F Eisenga; Maxime Rappaport; Kristine Chua; Bo Qiao; Grace Jung; Victoria Gabayan; Barbara Gales; Georgina Ramos; Maarten A de Jong; Jelmer J van Zanden; Martin H de Borst; Stephan J L Bakker; Elizabeta Nemeth; Isidro B Salusky; Carlo A J M Gaillard; Tomas Ganz Journal: Nephrol Dial Transplant Date: 2019-12-01 Impact factor: 5.992